According to Zacks, “Vivos Therapeutics Inc. is a medical technology company. It engages in the development and commercialization of technology solutions for patients with sleep disordered breathing comprising mild-to-moderate obstructive sleep apnea. Vivos Therapeutics Inc. is based in Highlands Ranch, Colorado. “
Separately, Roth Capital reduced their price objective on shares of Vivos Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, August 13th.
Vivos Therapeutics (NASDAQ:VVOS) last released its earnings results on Thursday, August 12th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.01). The company had revenue of $4.50 million for the quarter, compared to analyst estimates of $3.70 million. On average, research analysts predict that Vivos Therapeutics will post -0.7 EPS for the current year.
A number of hedge funds have recently bought and sold shares of VVOS. BlackRock Inc. acquired a new position in Vivos Therapeutics in the first quarter valued at about $77,000. Geode Capital Management LLC acquired a new position in Vivos Therapeutics in the first quarter valued at about $82,000. Avalon Investment & Advisory acquired a new position in Vivos Therapeutics during the first quarter worth about $1,125,000. Alpha Paradigm Partners LLC acquired a new position in Vivos Therapeutics during the first quarter worth about $66,000. Finally, Citadel Advisors LLC acquired a new position in Vivos Therapeutics during the first quarter worth about $105,000. 10.29% of the stock is owned by institutional investors and hedge funds.
About Vivos Therapeutics
Vivos Therapeutics, Inc, a medical technology company, engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing, such as mild-to-moderate obstructive sleep apnea (OSA). Its treatment, the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of mild to moderate OSA.
See Also: What is a stock portfolio tracker?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.